N/A N=66 B40 Non-Invasive Blood Pressure Equivalency Study
Blood Pressure
Primary: Difference Between the B40 Monitor and Reference Device DINAMAP PRO1000 on NIBP Measurements — -1.4; -3.3; -3.7 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=59 Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose) — 6; 1…
N/A N=51 Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1
Alcohol Use · Drug Use · Risk Behavior
Primary: Percentage of Monthly Urine Samples That Are Negative for Cocaine — 51.8; 79.3 percentage of urine samples — p=.004
Phase 1 N=13 Nonconvulsive Electrotherapy: a Proof-of-concept Trial
Depressive Disorder · Bipolar Disorder · Schizoaffective Disorder
Primary: Change in Score on the 17-item Hamilton Depression Rating Scale — -11.6 units on a scale — p=0.001
N/A N=152 A Therapeutic Workplace to Address Poverty and Substance Use
Substance Use Disorders
Primary: Alcohol Abstinence — 82.8; 60.2 percentage of participants — p=<0.001
Phase 3 N=32 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
Phase 3 N=214 Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
HER2-positive Breast Cancer
Primary: Breast Pathological Complete Response (bpCR) — 71; 73 Participants — p=0.54
N/A N=353 Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Phase 4 N=672 A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)
Asthma
Primary: Change From Baseline in the Average AM Peak Expiratory Flow (PEF) Over the 7 Days of Week 8. — 361.8; 374.3; 348.4; 6.03 liters/minute — p=0.654
Phase 3 N=14 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) — 9; NA Months
Phase 2 N=84 Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Sjögren's Syndrome · Sjogren's Syndrome
Primary: Change From Baseline to Week 12 in ESSDAI Score — -5.60; -5.29 score on a scale
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
N/A N=10 A Pilot Study Investigating the Use of a Therapeutic Wand in Addition to Physiotherapy for Bladder Pain Syndrome
Painful Bladder Syndrome
Primary: Change in O'Leary-Sant Interstitial Cystitis Symptom Index Score — -4.25; -6.2; 0; -1.8 units on a scale
Phase 2 N=415 ARJ C13 Urea Breath Test System
H. Pylori Infection
Primary: Overall Percent Agreement — 98.40; 99.20 percentage of pos. agreement
N/A N=2,595 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
Sudden Cardiac Death
Primary: All-Cause Shock — 129; 178 Participants — p=0.005